Article info

Download PDFPDF

Original research
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

Authors

  1. Correspondence to Dr Kathleen DeRose; kathleen.2.derose{at}gsk.com
View Full Text

Citation

Zhang F, Zheng J, Li Y, et al
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

Publication history

  • Received March 16, 2021
  • Accepted December 14, 2021
  • First published April 15, 2022.
Online issue publication 
April 15, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.